FDA Cardio-Renal Drugs Advisory Committee
Executive Summary
Will discuss problems in antihypertensive drug development, using ACE inhibitors as an example, on the first day of its June 6-7 meeting. On the second day, the panel will review Lederle's Monocor (bisoprolol) as a once-daily treatment for hypertension and Marion Merrell Dow's I.V. formulation of Cardizem (diltiazem) for treating supraventricular tachycardia. Lederle licenses bisoprolol, a third- generation cardioselective beta blocker, from E. Merck. The meeting will be held in Masur Auditorium on the NIH campus, beginning at 9 a.m. each day.